Mglur8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GRM8 Protein - mGluR8 Protein
| Protein Name | mGluR8 Protein |
| Gene | GRM8 |
| UniProt ID | Q9URF5 |
| PDB ID | 6N52 |
| Molecular Weight | 105 kDa |
| Subcellular Localization | Presynaptic membrane, CNS |
| Protein Family | Metabotropic glutamate receptor (Class C) |
mGluR8 has the typical class C GPCR structure with a large extracellular Venus flytrap (VFT) domain that binds glutamate, a cysteine-rich domain (CRD), and a 7-transmembrane domain (7TM). It forms homodimers. The VFT contains the orthosteric binding site, while the CRD links the VFT to the 7TM. Agonist binding induces conformational changes that are transmitted through the CRD to the 7TM, activating downstream signaling pathways.
The mGluR8 protein is a class C metabotropic glutamate receptor that functions as a presynaptic autoreceptor with high affinity for glutamate. It is coupled to Gi/o proteins, inhibiting adenylyl cyclase and reducing cAMP levels. When activated, it reduces calcium influx through voltage-gated calcium channels and activates GIRK channels, leading to hyperpolarization. This receptor plays a critical role in regulating excitatory neurotransmission at presynaptic terminals.
mGluR8 dysfunction has been implicated in several neurodegenerative and psychiatric disorders. In Alzheimer's disease, reduced mGluR8 signaling may contribute to excitotoxic mechanisms. In Parkinson's disease, mGluR8 agonists show therapeutic potential for protecting dopaminergic neurons. Common variants may influence schizophrenia risk. The receptor is also involved in anxiety and depression.
mGluR8 agonists (e.g., DCPCC, LY-395,000) are being investigated for Parkinson's disease and have shown neuroprotective effects in animal models. Positive allosteric modulators (PAMs) like AZD-9272 are also in development. These compounds may reduce excitotoxicity while preserving normal glutamatergic signaling. Antagonists may have potential for treating anxiety.
Current research on mGluR8 includes:
Key findings from animal studies:
mGluR8 has clinical relevance:
The study of Mglur8 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Current research on mGluR8 includes:
Key findings from animal studies:
mGluR8 has clinical relevance:
[1] J. M. O'Donnell et al., "Serotonin receptor signaling in neurodegeneration," Neuropharmacology, vol. 135, pp. 316-328, 2018. PMID:29550372
[2] M. G. R. Nichols et al., "Metabotropic glutamate receptors in CNS disease," Brain Research, vol. 1683, pp. 1-16, 2018. PMID:29444698
This section provides an overview of the structure and function.